D L Hertz1, K M Kidwell2, S G Hilsenbeck3,4, S Oesterreich3,5, C K Osborne3,4, S Philips6, C Chenault3, R J Hartmaier3, T C Skaar6, M J Sikora7, J M Rae8. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St, Room 3054, Ann Arbor, MI, 48109-1065, USA. DLHertz@med.umich.edu. 2. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. 3. Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA. 4. Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 5. Department of Pharmacology and Chemical Biology, Women's Cancer Research Center, Magee Women's Research Institute, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA. 6. Indiana University School of Medicine, Indianapolis, IN, USA. 7. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 8. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Abstract
PURPOSE: A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation to endoxifen. Studies have provided conflicting data, and meta-analyses suggest a small but significant increase in cancer recurrence, necessitating additional studies to allow for accurate effect assessment. We conducted a retrospective pharmacogenomic analysis of a prospectively collected community-based cohort of patients with estrogen receptor-positive breast cancer to test for associations between low-activity CYP2D6 genotype and disease outcome in 500 patients treated with adjuvant tamoxifen monotherapy and 500 who did not receive any systemic adjuvant therapy. METHODS: Tumor-derived DNA was genotyped for common, functionally consequential CYP2D6 polymorphisms (*2, *3, *4, *6, *10, *41, and copy number variants) and assigned a CYP2D6 activity score (AS) ranging from none (0) to full (2). Patients with poor metabolizer (AS = 0) phenotype were compared to patients with AS > 0 and in secondary analyses AS was analyzed quantitatively. Clinical outcome of interest was recurrence free survival (RFS) and analyses using long-rank test were adjusted for relevant clinical covariates (nodal status, tumor size, etc.). RESULTS: CYP2D6 AS was not associated with RFS in tamoxifen treated patients in univariate analyses (p > 0.2). In adjusted analyses, increasing AS was associated with inferior RFS (Hazard ratio 1.43, 95% confidence interval 1.00-2.04, p = 0.05). In patients that did not receive tamoxifen treatment, increasing CYP2D6 AS, and AS > 0, were associated with superior RFS (each p = 0.0015). CONCLUSIONS: This population-based study does not support the hypothesis that patients with diminished CYP2D6 activity achieve inferior tamoxifen benefit. These contradictory findings suggest that the association between CYP2D6 genotype and tamoxifen treatment efficacy is null or near null, and unlikely to be useful in clinical practice.
PURPOSE: A number of studies have tested the hypothesis that breast cancerpatients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation to endoxifen. Studies have provided conflicting data, and meta-analyses suggest a small but significant increase in cancer recurrence, necessitating additional studies to allow for accurate effect assessment. We conducted a retrospective pharmacogenomic analysis of a prospectively collected community-based cohort of patients with estrogen receptor-positive breast cancer to test for associations between low-activity CYP2D6 genotype and disease outcome in 500 patients treated with adjuvant tamoxifen monotherapy and 500 who did not receive any systemic adjuvant therapy. METHODS:Tumor-derived DNA was genotyped for common, functionally consequential CYP2D6 polymorphisms (*2, *3, *4, *6, *10, *41, and copy number variants) and assigned a CYP2D6 activity score (AS) ranging from none (0) to full (2). Patients with poor metabolizer (AS = 0) phenotype were compared to patients with AS > 0 and in secondary analyses AS was analyzed quantitatively. Clinical outcome of interest was recurrence free survival (RFS) and analyses using long-rank test were adjusted for relevant clinical covariates (nodal status, tumor size, etc.). RESULTS:CYP2D6AS was not associated with RFS in tamoxifen treated patients in univariate analyses (p > 0.2). In adjusted analyses, increasing AS was associated with inferior RFS (Hazard ratio 1.43, 95% confidence interval 1.00-2.04, p = 0.05). In patients that did not receive tamoxifen treatment, increasing CYP2D6AS, and AS > 0, were associated with superior RFS (each p = 0.0015). CONCLUSIONS: This population-based study does not support the hypothesis that patients with diminished CYP2D6 activity achieve inferior tamoxifen benefit. These contradictory findings suggest that the association between CYP2D6 genotype and tamoxifen treatment efficacy is null or near null, and unlikely to be useful in clinical practice.
Authors: Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart Journal: Clin Pharmacol Ther Date: 2006-07 Impact factor: 6.875
Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875
Authors: L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce Journal: Clin Pharmacol Ther Date: 2011-03-23 Impact factor: 6.875
Authors: Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren Journal: Breast Cancer Res Date: 2005-01-28 Impact factor: 6.466
Authors: Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti Journal: Pharmgenomics Pers Med Date: 2022-06-21
Authors: Jennifer D Brooks; Elizabeth A Comen; Anne S Reiner; Irene Orlow; Siok F Leong; Xiaolin Liang; Lene Mellemkjær; Julia A Knight; Charles F Lynch; Esther M John; Leslie Bernstein; Meghan Woods; David R Doody; Kathleen E Malone; Jonine L Bernstein Journal: Breast Cancer Res Date: 2018-12-10 Impact factor: 6.466
Authors: Ibrahim Malash; Osman Mansour; Sabry Shaarawy; Mona S Abdellateif; Anan Omar; Rabab Gaafer; Abdel-Rhaman N Zekri; Ola S Ahmed; Abeer Bahnassy Journal: Asian Pac J Cancer Prev Date: 2020-12-01